Fig 3.

Comparison of blood pressure and nuclear factor–κB (NF-κB) activity after 7 days treatment with angiotensin II (Ang II) (day 7 Ang), heat shock (HS) and 7 days treatment with Ang II (HS + d7 Ang), vasodilator eprosartan and 7 days treatment with Ang II (Epro + d7 Ang), vasodilator hydralazine and 7 days treatment with Ang II (Hydra + d7 Ang), and 7 days treatment with norepinephrine (d7 NE). (A) Systolic blood pressure. **P < 0.01 vs d7 Ang II infused. Each bar represents the data from 6 rats. (B) NF-κB activity in aorta. (C) Semiquantitative densitometry of NF-κB activity in aorta. **P < 0.01 vs d7 Ang II infused. There are also significant differences (P < 0.01) between HS + d7 Ang vs Epro + d7 Ang and d7 NE and between Hydra + d7 Ang vs Epro + d7 Ang and d7 NE. Data are representative of 3 separate experiments